{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:52:56Z","timestamp":1790290376608,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2955,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001458","name":"American Kennel Club Canine Health Foundation","doi-asserted-by":"publisher","award":["01426"],"award-info":[{"award-number":["01426"]}],"id":[{"id":"10.13039\/100001458","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCATS Colorado CTSI","award":["UL1 TR001082"],"award-info":[{"award-number":["UL1 TR001082"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>KIT inhibitors, such as toceranib (TOC), and vinblastine (VBL) have not been prospectively compared in the treatment of macroscopic mast cell tumors (MCTs). Also, it is unknown whether VBL or TOC is superior for treating MCT without c-kit mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>To determine the value of KIT genotyping and localization in treatment decisions for dogs with macroscopic MCT. We hypothesized that c-kit mutated MCT would have a better response to TOC than VBL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Eighty-eight client-owned dogs with macroscopic MCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, randomized trial. Dogs were randomized to TOC (2.75 mg\/kg EOD) or VBL (2.5 mg\/m2 weekly \u00d7 4 then EOW) by KIT localization and c-kit mutation status using an adaptive randomization scheme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty dogs were allocated to TOC and 28 to VBL. Of the dogs receiving TOC, 20% had c-kit mutations, compared to 30% receiving VBL (P = 0.74). Overall response rates were 46% (TOC) and 30% (VBL) (odds ratio = 1.56 [0.62\u20133.92]; P = 0.28). Median progression-free survival (PFS) for dogs receiving VBL was 78 days (7\u20131,521) and for TOC 95.5 (14\u2013990); hazard ratio (HR) = 1.34 [0.72\u20132.50]; P = 0.36. Median overall survival (OS) was 241.5 days (10\u20131,521) for the VBL group and 159 (20\u2013990) for the TOC group; HR = 0.80 ([0.45\u20131.41]; P = 0.44).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Neither PFS nor OS was significantly different between treatment groups. As the proportion of dogs with c-kit mutations was not different between treatment groups in this population of dogs, c-kit mutation status did not predict treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.14889","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T11:44:04Z","timestamp":1512042244000},"page":"394-405","source":"Crossref","is-referenced-by-count":47,"title":["c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2827-2246","authenticated-orcid":false,"given":"K.M.","family":"Weishaar","sequence":"first","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University Department of Clinical Sciences, , Fort Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Ehrhart","sequence":"additional","affiliation":[{"name":"Immunology, and Pathology, Flint Animal Cancer Center, Colorado State University Department of Microbiology, , Fort Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Avery","sequence":"additional","affiliation":[{"name":"Immunology, and Pathology, Flint Animal Cancer Center, Colorado State University Department of Microbiology, , Fort Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Charles","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University Department of Clinical Sciences, , Fort Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.E.","family":"Elmslie","sequence":"additional","affiliation":[{"name":"VRCC Veterinary Specialty and Emergency Hospital , Englewood, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Vail","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine and the Carbone Cancer Center, University of Wisconsin-Madison , Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"London","sequence":"additional","affiliation":[{"name":"The Ohio State University Veterinary Medical Center , Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Clifford","sequence":"additional","affiliation":[{"name":"Red Bank Veterinary Hospital , Tinton Falls, NJ"},{"name":"HOPE Veterinary Specialists , Malvern, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Eickhoff","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine and the Carbone Cancer Center, University of Wisconsin-Madison , Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7767","authenticated-orcid":false,"given":"D.H.","family":"Thamm","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University Department of Clinical Sciences, , Fort Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,1]]},"reference":[{"key":"2026020303253405200_jvim14889-bib-0001","first-page":"335","article-title":"Small Animal Clinical Oncology","author":"London","year":"2013","edition":"5"},{"key":"2026020303253405200_jvim14889-bib-0002","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1354\/vp.39-5-529","article-title":"Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs","volume":"39","author":"Zemke","year":"2002","journal-title":"Vet Pathol"},{"key":"2026020303253405200_jvim14889-bib-0003","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1593\/neo.05622","article-title":"The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors","volume":"8","author":"Webster","year":"2006","journal-title":"Neoplasia"},{"key":"2026020303253405200_jvim14889-bib-0004","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2460\/ajvr.2002.63.1718","article-title":"Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-KIT in mast cell tumors of dogs","volume":"63","author":"Downing","year":"2002","journal-title":"Am J Vet Res"},{"key":"2026020303253405200_jvim14889-bib-0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1354\/vp.44-3-298","article-title":"Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication","volume":"44","author":"Webster","year":"2007","journal-title":"Vet Pathol"},{"key":"2026020303253405200_jvim14889-bib-0006","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1746-6148-4-32","article-title":"Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone","volume":"13","author":"Webster","year":"2008","journal-title":"BMC Vet Res"},{"key":"2026020303253405200_jvim14889-bib-0007","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7150\/ijms.1.101","article-title":"Tyrosine kinase \u2013 role and significance in cancer","volume":"1","author":"Paul","year":"2004","journal-title":"Int J Med Sci"},{"key":"2026020303253405200_jvim14889-bib-0008","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1038\/onc.2008.326","article-title":"Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling","volume":"27","author":"Ischenko","year":"2008","journal-title":"Oncogene"},{"key":"2026020303253405200_jvim14889-bib-0009","first-page":"673","article-title":"siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K\/Akt-dependent pathway","volume":"18","author":"Liu","year":"2007","journal-title":"Oncol Rep"},{"key":"2026020303253405200_jvim14889-bib-0010","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1593\/neo.91438","article-title":"c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1\/2","volume":"12","author":"Tang","year":"2010","journal-title":"Neoplasia"},{"key":"2026020303253405200_jvim14889-bib-0011","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","article-title":"Masitinib is safe and effective for the treatment of canine mast cell tumors","volume":"22","author":"Hahn","year":"2008","journal-title":"J Vet Intern Med"},{"key":"2026020303253405200_jvim14889-bib-0012","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multi-center, placebo-controlled, doubleblind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision","volume":"15","author":"London","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026020303253405200_jvim14889-bib-0013","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/jsap.12480","article-title":"Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumors","volume":"57","author":"Grant","year":"2016","journal-title":"J Small Anim Pract"},{"key":"2026020303253405200_jvim14889-bib-0014","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/ncb2257","article-title":"A direct role for met endocytosis in tumorigenesis","volume":"13","author":"Joffre","year":"2011","journal-title":"Nat Cell Biol"},{"key":"2026020303253405200_jvim14889-bib-0015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1939-1676.1999.tb02217.x","article-title":"Treatment of canine mast cell tumors with CCNU (lomustine)","volume":"13","author":"Rassnick","year":"1999","journal-title":"J Vet Intern Med"},{"key":"2026020303253405200_jvim14889-bib-0016","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1939-1676.2012.00897.x","article-title":"A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs","volume":"26","author":"Vail","year":"2012","journal-title":"J Vet Intern Med"},{"key":"2026020303253405200_jvim14889-bib-0017","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1892\/0891-6640(1999)013<0491:PAVCFC>2.3.CO;2","article-title":"Prednisone and vinblastine chemotherapy for canine mast cell tumor \u2013 41 cases (1992\u20131997)","volume":"13","author":"Thamm","year":"1999","journal-title":"J Vet Intern Med"},{"key":"2026020303253405200_jvim14889-bib-0018","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1476-5829.2006.00125.x","article-title":"Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997\u20132004)","volume":"5","author":"Camps-Palau","year":"2007","journal-title":"Vet Comp Oncol"},{"key":"2026020303253405200_jvim14889-bib-0019","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1476-5829.2009.00190.x","article-title":"Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases","volume":"7","author":"Cooper","year":"2009","journal-title":"Vet Comp Oncol"},{"key":"2026020303253405200_jvim14889-bib-0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1476-5810.2004.0053b.x","article-title":"Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0","volume":"2","author":"Vale","year":"2004","journal-title":"Vet Comp Oncol"},{"key":"2026020303253405200_jvim14889-bib-0021","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1354\/vp.41-4-371","article-title":"The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors","volume":"41","author":"Kiupel","year":"2004","journal-title":"Vet Pathol"},{"key":"2026020303253405200_jvim14889-bib-0022","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/030098588402100503","article-title":"Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs","volume":"21","author":"Patnaik","year":"1984","journal-title":"Vet Pathol"},{"key":"2026020303253405200_jvim14889-bib-0023","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/1541-7786.MCR-08-0067","article-title":"Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors","volume":"6","author":"Letard","year":"2008","journal-title":"Mol Cancer Res"},{"key":"2026020303253405200_jvim14889-bib-0024","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/1740774510372657","article-title":"A Bayesian adaptive design with biomarkers for targeted therapies","volume":"7","author":"Eickhoff","year":"2010","journal-title":"Clin Trials"},{"key":"2026020303253405200_jvim14889-bib-0025","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/vco.12032","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"13","author":"Nguyen","year":"2015","journal-title":"Vet Comp Oncol"},{"key":"2026020303253405200_jvim14889-bib-0026","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1939-1676.2011.00851.x","article-title":"Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors","volume":"26","author":"Carlsten","year":"2012","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.14889","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/32\/1\/394\/66672763\/jvim14889.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/32\/1\/394\/66672763\/jvim14889.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:25:47Z","timestamp":1770107147000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/32\/1\/394\/8449763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.14889","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2018,1,1]]}}}